ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

  • EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical Trials
  • Technology Platform with Potential to Generate Robust Antiviral Therapies
  • Founded by VIB, UCB Ventures and Fund+


Belgium, July 28th, 2020: ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19.


Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...